The following is a summary of the Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript:
Financial Performance:
Oncternal reported grant revenue of $0.8 million for Q2 2024.
Total operating expenses for Q2 2024 were $9.7 million, with research and development accounting for $6.6 million, and general and administrative expenses totaling $3.1 million.
Net loss for the quarter was $8.6 million, with a net loss per share of $2.89.The company has approximately $21.4 million in cash and equivalents, expecting to support operations into Q1 2025.
Business Progress:
ONCT-534, a dual-action androgen receptor inhibitor, is advancing in a Phase I/II study, with the sixth dosing cohort fully enrolled.
ONCT-808, an autologous CAR-T cell therapy targeting ROR1, is ongoing in a Phase I/II study for relapsed or refractory aggressive B-cell lymphoma.
Opportunities:
Pending clinical updates and data readouts for ONCT-534 and ONCT-808 could potentially enhance Oncternal's portfolio and market position in cancer therapies.
Risks:
The clinical advancement of ONCT-534 and ONCT-808 includes inherent risks tied to safety profile and efficacy outcomes, crucial for subsequent regulatory and development milestones.
More details: Oncternal Therapeutics IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
